---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025640"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:47:21.055314+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Karyopharm files 1-for-15 reverse stock split effective Feb 25 to meet Nasdaq bid price rule

## Summary
- Reverse stock split 1-for-15 effective Feb 25, 2025 at 5pm ET; post-split trading starts Feb 26.
- Authorized shares reduced to 53,333,333; no fractional shares, cash paid in lieu.
- Equity awards, warrants, and convertible notes adjusted proportionally.
- New CUSIP number for common stock after split is 48576U205.
- Purpose: regain compliance with Nasdaq minimum $1.00 bid price continued listing requirement.

## SEC filing metadata
- accession: 0000950170-25-025640
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025025640/0000950170-25-025640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025025640/kpti-20250224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025640
- JSON: https://secwatch.observer/filing/0000950170-25-025640.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025640.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.